Piracetam reverses haloperidol-induced catalepsy in mice

To investigate the memory-enhancing drugs piracetam, vinpocetine, and ginkgo biloba for their ability to reduce catalepsy in mice treated with haloperidol. Haloperidol is a classic neuroleptic drug that induces motor abnormalities and cognitive impairment due to a blockade of dopamine D2 receptors in the striatum. Materials and methods: Catalepsy was induced by intraperitoneal haloperidol (2 mg/kg) administration. The drugs being tested were either administered intraperitoneally (IP) along with the dosage of haloperidol or 30 min prior to the introduction of the haloperidol. Catalepsy was measured using the bar test. Results: The administration of haloperidol (2 mg/kg, IP) resulted in significant catalepsy. Piracetam (in dosages of 50, 100, and 300 mg/kg) given IP at the time of haloperidol administration reduced the duration of catalepsy by 24.4%, 32.3%, and 48.2%, respectively. Piracetam given as a 30-min pretreatment reduced the duration of catalepsy by 59.5%, 72.3%, and 78.2%, respectively. Vinpocetine coadministered IP with haloperidol did not modify catalepsy, but given as a 30-min pretreatment, the drug increased catalepsy duration by 53.5%, 53.6%, and 65.1%, respectively. Ginkgo biloba coadministered IP with haloperidol at 25, 50, or 150 mg/kg increased catalepsy duration by 13.6%-17.1%. Ginkgo biloba given 30 min prior to haloperidol increased catalepsy duration by 29.1%, 35.1%, and 37.2%, respectively. Conclusion: The present study indicates that the nootropic drug piracetam reduces haloperidol-induced catalepsy in mice.

Anahtar Kelimeler:

Key words: Catalepsy, haloperidol, piracetam, vinpocetine, ginkgo biloba, mice

Piracetam reverses haloperidol-induced catalepsy in mice

Keywords:

Key words: Catalepsy, haloperidol, piracetam, vinpocetine, ginkgo biloba, mice,

PDF

___

Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. PET-analysis of central D-2 and D2-dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side eff ects. Archl Gen Psychiatry 1992; 49: 538-44.
Hoff man DC, Donovan H. Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side eff ect liability. Psychopharmacology 1995; 120: 128-33.
Legangneux E, McEwen J, Wesnes K, Berougnan L, Miget N, Canal M et al. Th e acute eff ects of amisulpride (50 mg and 200 mg) and haloperidol (2 mg) on cognitive function in healthy elderly volunteers. Journal of Psychopharmacology 2000; 14: 164-71.
Harrison BE, Th errien B. Eff ect of antipsychotic medication use on memory in patients with Alzheimer’s disease: Assessing the potential risk for accelerated recent autobiographical memory loss. J Gerontol Nurs 2007; 33: 11-20.
Shorvon S. Pyrrolidone derivatives. Lancet 2001; 358: 1885-92.
Kessler J, Th iel A, Karbe H, Heiss WD. Piracetam improves activated blood fl ow and facilitates rehabilitation of poststroke aphasic patients. Stroke 2000; 31: 2112-6.
Waegemans T, Wilsher CR, Danniau A, Ferris SH, Kurz A, Winblad B. Clinical effi cacy of piracetam in cognitive impairment: a meta-analysis. Dement Geriatr Cogn Disord 2002; 13: 217-24.
Holinski S, Claus B, Alaaraj N, Dohmen PM, Kirilova K, Neumann K et al. Cerebroprotective eff ect of piracetam in patients undergoing coronary bypass surgery. Med Sci Monit 2008; 14: PI53-7.
Ince GD, Agan K, Afsar N, Borucu D, Us O. Th e eff ect of piracetam on ataxia: clinical observations in a group of autosomal dominant cerebellar ataxia patients. J Clin Pharm Th er 2008; 33: 175-8.
Kalmar S. Adjuvant therapy with parenteral piracetam in alcohol withdrawal delirium. Orv Hetil 2003; 144: 927-30.
Vas A, Gulyas B, Szabo Z, Bonoczk P, Csiba L, Kiss B et al. Clinical and non-clinical investigations using positron emission tomography, near infrared spectroscopy and transcranial Doppler methods on the neuroprotective drug vinpocetine: a summary of evidences. J Neurol Sci 2002; 203-4: 259-62.
Valikovics A. Investigation of the eff ect of vinpocetine on cerebral blood fl ow and cognitive functions. Ideggyogy Sz 2007; 60: 301-10.
DeNoble VJ, Repetti SJ, Gelpke LW, Wood LM, Keim KL. Vinpocetine: nootropic eff ects on scopolamine-induced and hypoxia-induced retrieval defi cits of a step-through passive avoidance response in rats. Pharmacol Biochem Behav 1986; 24: 1123-8.
Bhatti JZ, Hindmarch I. Vinpocetine eff ects on cognitive impairments produced by fl Psychopharmacol 1987; 2: 325-31.
unitrazepam. Int Clin
Van Staveren WCG, Markerink Ittersum M, Steinbusch HW, de Vente J. Th e eff ects of phosphodiesterase inhibition on cyclic GMP and cyclic AMP accumulation in the hippocampus of the rat. Brain Res 2001; 888: 275-86.
Sitges M, Galvan E, Nekrassov V. Vinpocetine blockade of sodium channels inhibits the rise in sodium and calcium induced by 4-aminopyridine in synaptosomes. Neurochem Int 2005; 46: 533-40.
Santos MS, Duarte AI, Moreira PI, Oliveira CR. Synaptosomal response to oxidative stress: Eff ect of vinpocetine. Free Radic Res 2000; 32: 57-66.
DeFeudis FV, Drieu K. Ginkgo biloba extract (EGb 761) and CNS functions: basic studies and clinical applications. Curr Drug Targets 2000; 1: 25-58.
Oken BS, Strozbach DM, Kaye JA. Th e effi cacy of Ginkgo biloba on cognitive function in Alzheimer disease. Arch Neurol 1998; 55: 1409-15.
Schindowski K, Leutner S, Kressmann S, Eckert A, Müller WE. Age-related increase of oxidative stress-induced apoptosis in mice prevention by Ginkgo biloba extract (EGb761). J Neural Transm 2001; 108: 969-78.
Abdel-Salam OME, Baiuomy AR, El-Batran S, Arbid MS. Evaluation of the anti-infl ammatory, anti-nociceptive and gastric eff ects of ginkgo biloba in the rat. Pharmacol Res 2004; 49: 133-42.
Chung HS, Harris A, Kristinsson JK, Ciulla TA, Kagemann C, Ritch R. Ginkgo biloba extract increases ocular blood fl ow velocity. J Ocul Pharmacol Th er 1999; 15: 233-40.
Jung F, Mrowietz C, Kiesewetter H, Wenzel E. Eff ect of Ginkgo biloba on fl uidity of blood and peripheral microcirculation in volunteers. Arzneimittelforschung 1990; 40: 589-93.
Korth R, Nunez D, Bidault J, Benveniste J. Comparison of three paf-acether receptor antagonist ginkgolides. Eur J Pharmacol 1988; 152: 101-10.
Fedi M, Reutens D, Dubeau F, Andermann E, D’Agostino D, Andermann F.Long-term effi cacy and safety of piracetam in the treatment of progressive myoclonus epilepsy. Arch Neurol 2001; 58: 781-6.
Libov I, Miodownik C, Bersudsky Y, Dwolatzky T, Lerner V. Effi cacy of piracetam in the treatment of tardive dyskinesia in schizophrenic patients: a randomized, double-blind, placebo- controlled crossover study. J Clin Psychiatry 2007; 68: 1031-7.
Tarnawa I, Bölcskei H, Kocsis P. Blockers of voltage-gated sodium channels for the treatment of central nervous system diseases. Recent Patents on CNS Drug Discovery 2007; 2: 57- 78.
Keim KL, Hall PC. General neuropharmacology of vinpocetine: A putative cerebral activator. Drug Development Research 2004; 11: 107-15.
Lin CC, Cheng WL, Hsu SH, Chang CM. Th e eff ects of Ginkgo biloba extracts on the memory and motor functions of rats with chronic cerebral insuffi ciency. Neuropsychobiology 2003; 47: 47-51.
Stancheva SL, Alova LG. Biogenic monoamine uptake by rat brain synaptosomes during aging. Eff ects of nootropic drugs. Gen Pharmacol 1994; 25: 981-7.
Budygin EA, Gaĭnetdinov RR, Titov DA, Kovalev GI. Th e eff ect of a low dose of piracetam on the activity of the dopaminergic system in the rat striatum. Eksp Klin Farmakol 1996; 59: 6-8.
Trejo F, Nekrassov V, Sitges M. Characterization of vinpocetine eff ects on DA and DOPAC release in striatal isolated nerve endings. Brain Res 2001; 909: 59-67.
Fehske CJ, Leuner K, Müller WE. Ginkgo biloba extract (EGb761) infl uences monoaminergic neurotransmission via inhibition of NE uptake, but not MAO activity aft er chronic treatment. Pharmacol Res 2009; 60: 68-73.
National Institute of Health. Guide for the care and use of laboratory animals, publication no. 85-23. Washington, DC: National Academies Press; 1985.
Paget GE, Barnes JM. Toxicity tests. In: Laurence DR, Bacharach AL, editors. Evaluation of drug activities pharmacometrics. London and New York: Academic Press; 1964. p.1-135.
Moratalla R, Xu M, Tonegawa S, Graybiel AM. Cellular responses to psychomotor stimulant and neuroleptic drugs are abnormal in mice lacking the D1 dopamine receptor. Proc Natl Acad Sci USA 1996; 93: 14928-33.
Wadenberg ML, Soliman A, VanderSpek SC, Kapur S. Dopamine D2 receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical eff ects. Neuropsychopharmacology 2001; 25: 633-41.
Góngora-Alfaro JL, Moo-Puc RE, Villanueva-Toledo JR, Alvarez-Cervera FJ, Bata-García JL, Heredia-López FJ et al. Long-lasting resistance to haloperidol-induced catalepsy in male rats chronically treated with caff eine. Neurosci Lett 2009; 463: 210-4.
Varty GB, Hodgson RA, Pond AJ, Grzelak ME, Parker EM, Hunter JC. Th e eff ects of adenosine A2A receptor antagonists on haloperidol-induced movement disorders in primates. Psychopharmacology 2008; 200: 393-401.
Imaki J, Mae Y, Shimizu S, Ohno Y. Th erapeutic potential of alpha2 adrenoceptor antagonism for antipsychotic-induced extrapyramidal motor disorders. Neurosci Lett 2009; 454: 143- 7.
Prinssen EP, Colpaert FC, Koek W. 5-HT1A receptor activation and anti-cataleptic eff ects: high-effi cacy agonists maximally inhibit haloperidol-induced catalepsy. Eur J Pharmacol 2002; 453: 217-21.
Niswender CM, Johnson KA, Weaver CD, Jones CK, Xiang Z, Luo Q et al. Discovery, characterization, and antiparkinsonian eff ect of novel positive allosteric modulators of metabotropic glutamate receptor 4. Mol Pharmacol 2008; 74: 1345-58.
Nowakowska E, Kus K, Krzyzanski W, Czubak A. Infl uence of haloperidol and clozapine on some behavioral eff ects in rats. Arzneimittelforschung 2006; 56: 807-13.
Müller WE, Koch S, Scheuer K, Rostock A, Bartsch R. Eff ects of piracetam on membrane fl uidity in the aged mouse, rat, and human brain. Biochem Pharmacol 1997; 53: 135-40.
Heiss WD, Hebold I, Klinkhammer P, Ziffl ing P, Szelies B, Pawlik G et al. Eff ect of piracetam on cerebral glucose metabolism in Alzheimer’s disease as measured by positron emission tomography. J Cereb Blood Flow Metab 1988; 8: 613- 7.
Akopian VP, Balian LS, Avetisian NA. Th e eff ect of hypokinesia on depression and on the central GABA-A receptor complexes in the rat brain. Eksp Klin Farmakol 2006; 69: 10-3.
Moldavkin GM, Voronina TA, Neznamov GG, Maletova OK, Eliava NV. Participation of GABA-benzodiazepine receptor complex in the anxiolytic eff ect of piracetam. Eksp Klin Farmakol 2006; 69: 7-9.
Pant KK, Nath C. Dopaminergic involvement in the eff ects of piracetam on foot shock induced aggression in mice. Indian J Med Res 1993; 98: 155-9.
Rägo LK, Allikmets LH, Zarkovsky AM. Eff ects of piracetam on the central dopaminergic transmission. Naunyn Schmiedebergs Arch Pharmacol 1981; 318: 36-7.
Gainetdinov RR, Raevskii KS. Substances increasing the extracellular content of dopamine in the striatum prevent the development of haloperidol catalepsy in rats. Bull Exp Biol Med 1996; 121: 399-401.
Kiss B, Cai NS, Erdö SL. Vinpocetine preferentially antagonizes quisqualate/AMPA receptor responses: evidence from release and ligand binding studies. Eur J Pharmacol 1991; 209: 109-12.
Lee DKH, Geiger G. Eff ect of vinpocetine on monoamine receptor binding and synaptosomal uptake in the rat brain. Drug Development Research 2004; 14: 281-3.
Meng H, Li C, Feng L, Cheng B, Wu F, Wang X et al. Eff ects of Ginkgolide B on 6-OHDA-induced apoptosis and calcium over load in cultured PC12. Int J Dev Neurosci 2007; 25: 509-14.
Rojas P, Serrano-García N, Mares-Sámano JJ, Medina-Campos ON, Pedraza-Chaverri J, Ogren SO. EGb761 protects against nigrostriatal dopaminergic neurotoxicity in 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice: role of oxidative stress. Eur J Neurosci 2008; 28: 41-50.
Su SY, Hsieh CL, Wu SL, Cheng WY, Li CC, Lo HY et al. Transcriptomic analysis of EGb 761-regulated neuroactive receptor pathway in vivo. J Ethnopharmacol 2009; 123: 68-73.
Blecharz-Klin K, Piechal A, Joniec I, Pyrzanowska J, Widy- Tyszkiewicz E. Pharmacological and biochemical eff ects of Ginkgo biloba extract on learning, memory consolidation and motor activity in old rats. Acta Neurobiol Exp (Wars) 2009; 69: 217-31.
Szasz BK, Lenkey N, Barth AM, Mike A, Somogyvari Z, Farkas O et al. Converging eff ects of Ginkgo biloba extract at the level of transmitter release, NMDA and sodium currents and dendritic spikes. Planta Med 2008; 74: 1235-9.
Fontana L, Souza AS, Del Bel EA, Oliveira RM. Ginkgo biloba leaf extract (EGb 761) enhances catalepsy induced by haloperidol and L-nitroarginine in mice. Braz J Med Biol Res 2005; 38: 1649-54.